(RTTNews) - Cipla USA Inc. the wholly owned subsidiary of Cipla Limited (500087, CIPLA) announced that it has received final approval from U.S. FDA for Abbreviated New Drug Application or ANDA for Nintedanib Capsules, 100 mg and 150 mg, for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The company is set to launch the product on an immediate basis, and it will be available through appropriate pharmacy distribution channels, including specialty distribution. Cipla's Nintedanib Capsules are the generic therapeutic equivalent of Ofev, marketed by Boehringer Ingelheim.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
